FI104374B - T-solu-epitooppi-oligopeptidejä ja niitä sisältävien konjugaattien valmistus - Google Patents

T-solu-epitooppi-oligopeptidejä ja niitä sisältävien konjugaattien valmistus Download PDF

Info

Publication number
FI104374B
FI104374B FI903292A FI903292A FI104374B FI 104374 B FI104374 B FI 104374B FI 903292 A FI903292 A FI 903292A FI 903292 A FI903292 A FI 903292A FI 104374 B FI104374 B FI 104374B
Authority
FI
Finland
Prior art keywords
crm
peptide
cell
prp
antigen
Prior art date
Application number
FI903292A
Other languages
English (en)
Finnish (fi)
Swedish (sv)
Other versions
FI903292A0 (fi
Inventor
Subramonia Pillai
Richard Insel
Garvin Bixler
Original Assignee
American Cyanamid Co
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by American Cyanamid Co filed Critical American Cyanamid Co
Publication of FI903292A0 publication Critical patent/FI903292A0/fi
Application granted granted Critical
Publication of FI104374B publication Critical patent/FI104374B/fi

Links

Classifications

    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • A61K39/385—Haptens or antigens, bound to carriers
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K47/00—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient
    • A61K47/50—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates
    • A61K47/51—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates the non-active ingredient being a modifying agent
    • A61K47/62—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates the non-active ingredient being a modifying agent the modifying agent being a protein, peptide or polyamino acid
    • A61K47/64—Drug-peptide, drug-protein or drug-polyamino acid conjugates, i.e. the modifying agent being a peptide, protein or polyamino acid which is covalently bonded or complexed to a therapeutically active agent
    • A61K47/646—Drug-peptide, drug-protein or drug-polyamino acid conjugates, i.e. the modifying agent being a peptide, protein or polyamino acid which is covalently bonded or complexed to a therapeutically active agent the entire peptide or protein drug conjugate elicits an immune response, e.g. conjugate vaccines
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K14/00—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
    • C07K14/195—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from bacteria
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • A61K2039/60—Medicinal preparations containing antigens or antibodies characteristics by the carrier linked to the antigen
    • A61K2039/6031—Proteins
    • A61K2039/6037—Bacterial toxins, e.g. diphteria toxoid [DT], tetanus toxoid [TT]
    • Y—GENERAL TAGGING OF NEW TECHNOLOGICAL DEVELOPMENTS; GENERAL TAGGING OF CROSS-SECTIONAL TECHNOLOGIES SPANNING OVER SEVERAL SECTIONS OF THE IPC; TECHNICAL SUBJECTS COVERED BY FORMER USPC CROSS-REFERENCE ART COLLECTIONS [XRACs] AND DIGESTS
    • Y02—TECHNOLOGIES OR APPLICATIONS FOR MITIGATION OR ADAPTATION AGAINST CLIMATE CHANGE
    • Y02A—TECHNOLOGIES FOR ADAPTATION TO CLIMATE CHANGE
    • Y02A50/00—TECHNOLOGIES FOR ADAPTATION TO CLIMATE CHANGE in human health protection, e.g. against extreme weather
    • Y02A50/30—Against vector-borne diseases, e.g. mosquito-borne, fly-borne, tick-borne or waterborne diseases whose impact is exacerbated by climate change

Landscapes

  • Health & Medical Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • General Health & Medical Sciences (AREA)
  • Molecular Biology (AREA)
  • Medicinal Chemistry (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Engineering & Computer Science (AREA)
  • Proteomics, Peptides & Aminoacids (AREA)
  • Epidemiology (AREA)
  • Animal Behavior & Ethology (AREA)
  • Public Health (AREA)
  • Veterinary Medicine (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Organic Chemistry (AREA)
  • Immunology (AREA)
  • Mycology (AREA)
  • Virology (AREA)
  • Gastroenterology & Hepatology (AREA)
  • Biochemistry (AREA)
  • Biophysics (AREA)
  • Genetics & Genomics (AREA)
  • Microbiology (AREA)
  • Medicines Containing Antibodies Or Antigens For Use As Internal Diagnostic Agents (AREA)
  • Peptides Or Proteins (AREA)
  • Optical Couplings Of Light Guides (AREA)
FI903292A 1988-02-01 1990-06-29 T-solu-epitooppi-oligopeptidejä ja niitä sisältävien konjugaattien valmistus FI104374B (fi)

Applications Claiming Priority (4)

Application Number Priority Date Filing Date Title
US15068888A 1988-02-01 1988-02-01
US15068888 1988-02-01
US8900388 1989-01-31
PCT/US1989/000388 WO1989006974A2 (fr) 1988-02-01 1989-01-31 Epitopes de cellules t a titre de molecules porteuses pour vaccins conjugues

Publications (2)

Publication Number Publication Date
FI903292A0 FI903292A0 (fi) 1990-06-29
FI104374B true FI104374B (fi) 2000-01-14

Family

ID=22535596

Family Applications (1)

Application Number Title Priority Date Filing Date
FI903292A FI104374B (fi) 1988-02-01 1990-06-29 T-solu-epitooppi-oligopeptidejä ja niitä sisältävien konjugaattien valmistus

Country Status (10)

Country Link
EP (1) EP0399001B1 (fr)
JP (1) JP2921574B2 (fr)
AT (1) ATE109008T1 (fr)
AU (1) AU634153B2 (fr)
CA (2) CA1340956C (fr)
DE (1) DE68917126T2 (fr)
DK (1) DK174416B1 (fr)
FI (1) FI104374B (fr)
NO (1) NO179164C (fr)
WO (1) WO1989006974A2 (fr)

Families Citing this family (36)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
JP2546544B2 (ja) * 1989-10-27 1996-10-23 アーチ ディベラップメント コーポレイション 免疫強化を促進するための方法と組成物
GB8924438D0 (en) * 1989-10-31 1989-12-20 Hoffmann La Roche Vaccine composition
US5500366A (en) * 1990-09-18 1996-03-19 Biotech Australia Pty. Ltd. Polynucleotide encoding T-cell epitopes of the protein TraT
WO1993011157A1 (fr) * 1991-11-27 1993-06-10 The Council Of The Queensland Institute Of Medical Research VACCIN ET PEPTIDES CONTRE LA MALARIA COMPRENANT UN EPITOPE DE CELLULE T HUMAINE DE PROTEINE CIRCUMSPOROZOITE DE $i(P.VIVAX)
IL105503A (en) * 1992-04-28 1999-05-09 Astra Ab Carbon peptide couplets capable of eliciting an immune response of T cells
AU4580093A (en) * 1992-07-22 1994-02-14 Proteus Molecular Design Limited Polypeptide antigens of mycobacterium bovis
CA2141427C (fr) * 1992-07-31 2008-07-22 Mohammed Anjam Khan Expression de proteines hybrides recombinantes dans des bacteries attenueees
BR9306984A (pt) 1992-08-27 1999-01-12 Deakin Res Ltd Análogo de antígeno de peptídeo de um antígeno de peptídeo nativo vacina anticorpo processo para vacinar um hospedeiro necessitando deste tratamento estojo diagnóstico processos para preparar um análogo de um antiígeno de um antígeno de peptídeo nativo para preparar uma vacina para analisar uma amostra para um antígeno de peptídeo nativo e para analisar uma amostra para um anticorpo
DK140992D0 (da) * 1992-11-24 1992-11-24 Ole Buchardt Fremgangsmaade til frembringelse af antistoffer mod haptener og andre b-celle-antigener, antistoffer opnaaet ved fremgangsmaaden og anvendelse af disse antistoffer til fremstilling af vacciner, isaer til veterinaermedicinsk brug
US5759551A (en) * 1993-04-27 1998-06-02 United Biomedical, Inc. Immunogenic LHRH peptide constructs and synthetic universal immune stimulators for vaccines
GB9401787D0 (en) 1994-01-31 1994-03-23 Medeva Holdings Bv Vaccine compositions
EP0712442B1 (fr) * 1993-07-30 2002-03-27 Medeva Holdings B.V. Compositions vaccinales
GB9401795D0 (en) * 1994-01-31 1994-03-23 Medeva Holdings Bv Vaccines
GB2295394B (en) * 1994-01-31 1997-09-24 Medeva Holdings Bv DNA encoding a fusion protein comprising the C fragment of tetanus toxin
AU1864195A (en) * 1994-03-07 1995-09-25 Auckland Uniservices Limited Prevention of diabetes
DE69630877T2 (de) * 1995-03-31 2004-11-11 Xenova Research Ltd., Slough Hapten-träger-konjugate zur anwendung in der drogen-missbrauchs-therapie
US5773003A (en) * 1995-03-31 1998-06-30 Immulogic, Inc. Hapten-carrier conjugates for use in drug-abuse therapy and methods for preparation of same
US5843462A (en) * 1995-11-30 1998-12-01 Regents Of The University Of Minnesota Diphtheria toxin epitopes
US7709002B1 (en) 1996-04-19 2010-05-04 The United States Of America As Represented By The Department Of Health And Human Services Mutated ras peptides for generation of CD8+Cytotoxic T lymphocytes
EP0895538B1 (fr) 1996-04-19 2002-07-17 THE GOVERNMENT OF THE UNITED STATES OF AMERICA, as represented by THE SECRETARY, DEPARTMENT OF HEALTH AND HUMAN SERVICES Peptides ras ayant subi une mutation et servant a generer des lymphocytes t cytotoxiques cd8+
GB9713156D0 (en) * 1997-06-20 1997-08-27 Microbiological Res Authority Vaccines
TWI229679B (en) 1998-06-20 2005-03-21 United Biomedical Inc Artificial T helper cell epitopes as immune stimulators for synthetic peptide immunogens
US6025468A (en) 1998-06-20 2000-02-15 United Biomedical, Inc. Artificial T helper cell epitopes as immune stimulators for synthetic peptide immunogens including immunogenic LHRH peptides
DE19856052A1 (de) * 1998-12-04 2000-06-08 Deutsches Krebsforsch Konjugat zur Anreicherung in neuronalen Zellen
AU2002231621A1 (en) 2000-11-09 2002-05-21 Immunolex Laboratories Method of producing antibodies by immunization with conjugates of molecules coupled to charge-modified proteins
KR20110084906A (ko) 2008-10-10 2011-07-26 에라 바이오테크, 에스.에이. 면역원-특이적 면역보강제로서의 재조합 단백질체들
US9358302B2 (en) * 2009-03-23 2016-06-07 The Brigham And Women's Hospital, Inc. Glycoconjugate vaccines
EP2418284A1 (fr) 2010-08-13 2012-02-15 ERA Biotech, S.A. Séquences de polypeptides induisant le corps protéiques
EP2870974A1 (fr) * 2013-11-08 2015-05-13 Novartis AG Vaccins conjugués de salmonelle
US9815886B2 (en) 2014-10-28 2017-11-14 Adma Biologics, Inc. Compositions and methods for the treatment of immunodeficiency
US11951165B2 (en) 2016-12-30 2024-04-09 Vaxcyte, Inc. Conjugated vaccine carrier proteins
KR20190103256A (ko) 2016-12-30 2019-09-04 수트로박스, 인코포레이티드 비자연 아미노산을 갖는 폴리펩타이드-항원 접합체
US10259865B2 (en) 2017-03-15 2019-04-16 Adma Biologics, Inc. Anti-pneumococcal hyperimmune globulin for the treatment and prevention of pneumococcal infection
AU2019299836A1 (en) 2018-07-04 2021-02-25 Vaxcyte, Inc. Improvements in immunogenic conjugates
WO2020010016A1 (fr) 2018-07-04 2020-01-09 Sutrovax, Inc. Conjugués immunogènes auto-adjuvés
WO2020010000A1 (fr) 2018-07-04 2020-01-09 Sutrovax, Inc. Procédés améliorés pour la préparation de conjugués immunogènes

Family Cites Families (3)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US4902506A (en) * 1983-07-05 1990-02-20 The University Of Rochester Immunogenic conjugates
US4808700A (en) * 1984-07-09 1989-02-28 Praxis Biologics, Inc. Immunogenic conjugates of non-toxic E. coli LT-B enterotoxin subunit and capsular polymers
NZ214503A (en) * 1984-12-20 1990-02-26 Merck & Co Inc Covalently-modified neutral bacterial polysaccharides, stable covalent conjugates of such polysaccharides and immunogenic proteins, and methods of preparing such polysaccharides and conjugates

Also Published As

Publication number Publication date
AU3065489A (en) 1989-08-25
DK182990D0 (da) 1990-07-31
CA1340958C (fr) 2000-04-11
NO179164C (no) 1996-08-21
DE68917126D1 (de) 1994-09-01
DE68917126T2 (de) 1995-02-02
AU634153B2 (en) 1993-02-18
CA1340956C (fr) 2000-04-11
DK174416B1 (da) 2003-02-17
WO1989006974A2 (fr) 1989-08-10
NO902909D0 (no) 1990-06-29
ATE109008T1 (de) 1994-08-15
JPH03502691A (ja) 1991-06-20
FI903292A0 (fi) 1990-06-29
DK182990A (da) 1990-07-31
EP0399001B1 (fr) 1994-07-27
NO902909L (no) 1990-08-27
NO179164B (no) 1996-05-13
WO1989006974A3 (fr) 1989-08-24
EP0399001A1 (fr) 1990-11-28
JP2921574B2 (ja) 1999-07-19

Similar Documents

Publication Publication Date Title
FI104374B (fi) T-solu-epitooppi-oligopeptidejä ja niitä sisältävien konjugaattien valmistus
US5785973A (en) Synthetic peptides representing a T-cell epitope as a carrier molecule for conjugate vaccines
AU634154B2 (en) Decoupled fiber optic feedthrough assembly
Paoletti et al. Effects of chain length on the immunogenicity in rabbits of group B Streptococcus type III oligosaccharide-tetanus toxoid conjugates.
US5425946A (en) Vaccines against group C Neisseria meningitidis
CA2142981C (fr) Vaccins contre neisseria meningitidis du groupe c
AU572821B2 (en) Synthetic heat-stable enterotoxin polypeptide of escherichia coli and multimers thereof
US5773007A (en) Vaccine compositions
EP0427347B1 (fr) Peptides synthétiques utiles comme porteurs universels pour la préparation des conjugués immunogéniques el leur emploi dans le développment des vaccins synthétiques
AU754890B2 (en) Enterococcus antigens and vaccines
KR101446238B1 (ko) 단백질 매트릭스 백신 및 그의 제조방법 및 백신 투여방법
Paoletti et al. An oligosaccharide-tetanus toxoid conjugate vaccine against type III group B Streptococcus.
PL174082B1 (pl) Koniugat kapsularnego polisacharydu (Vi) i związanego z nim nośnika oraz sposób wytwarzania koniugatu
JPH11507964A (ja) ２，５−アンヒドロ−ｄ−マンノース末端構造を持つ、抗原性グループｂ連鎖球菌▲ｉｉ▼型および▲ｉｉｉ▼型多糖断片とその複合ワクチン
US5043158A (en) Immunogenic compositions containing ordered carriers
BR112012009014B1 (pt) Processo para preparar conjugado de polissacarídeo capsular de s. aureus tipo 5 ou tipo 8 e molécula de transporte crm197, conjugado e composição imunogênica
Elsayed et al. Synthetic allergenic epitopes from the amino-terminal regions of the major allergens of hazel and birch pollen
EP0302887A1 (fr) Antigenes, anticorps, vaccins bacteriens et leur procede de production.
Richter et al. Preparation of dextran-protein conjugates and studies of their immunogenicity
Lett et al. Immunogenicity of polysaccharides conjugated to peptides containing T-and B-cell epitopes
Jennings Further approaches for optimizing polysaccharide-protein conjugate vaccines for prevention of invasive bacterial disease
Lugowski et al. Enterobacterial common antigen-tetanus toxoid conjugate as immunogen
WO1991012819A1 (fr) Compositions immunogeniques ameliorees
Michaelides Chemical and enzymatic fragmentation of tetanus toxin and immunological studies on anti-tetanus toxin and toxoid sera.

Legal Events

Date Code Title Description
FG Patent granted

Owner name: WYETH HOLDINGS CORPORATION

MA Patent expired